Idris, I. (2024). Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease. Wiley. https://doi.org/10.1002/doi2.89
Chicago Style (17th ed.) CitationIdris, Iskandar. Glucagon like Peptide‐1 (GLP‐1) Therapy Is Associated with Reduced Risk of Developing Cirrhosis and Liver Cancer in People with Type 2 Diabetes with Chronic Liver Disease. Wiley, 2024. https://doi.org/10.1002/doi2.89.
MLA (9th ed.) CitationIdris, Iskandar. Glucagon like Peptide‐1 (GLP‐1) Therapy Is Associated with Reduced Risk of Developing Cirrhosis and Liver Cancer in People with Type 2 Diabetes with Chronic Liver Disease. Wiley, 2024. https://doi.org/10.1002/doi2.89.
Warning: These citations may not always be 100% accurate.